FDA Approves Novartis' Iron Overload Treatment Exjade

Drug Industry Daily
KEYWORDS Drug Approvals / FDA
A A

The FDA has approved Novartis' new drug application (NDA) for Exjade, an oral alternative to a much more difficult treatment for patients suffering chronic iron overload from blood transfusions.

To View This Article:

Login

Subscribe To Drug Industry Daily